Clinical Trial Update: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of the FORTITUDE bioresorbable drug-eluting coronary stent by Amaranth Medical is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Ischemia

Drugs mentioned

• FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

Snippet

Sponsor: Amaranth Medical Inc. | Conditions: Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Status: UNKNOWN